3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
20
Leukemia, Myeloid, Acute
8
Recurrence
7
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma
3
Thymoma
2
Ovarian Neoplasms
2
Carcinoma
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Richter's Transformation
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
MDS
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Temozolomide
37
Radiotherapy
20
Bevacizumab
14
Carboplatin
10
Magnetic Resonance Spectroscopy
9
Carmustine
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Irinotecan
8
Filgrastim
7
Cyclophosphamide
6
Cisplatin
6
Etoposide
5
sargramostim
4
Vincristine
4
Thiotepa
4
Surgical Procedures, Operative
4
Specimen Handling
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Lomustine
4
Everolimus
4
Chemotherapy, Adjuvant
4
trametinib
3
aldesleukin
3
Topotecan
3
Thalidomide
3
Tamoxifen
3
Sunitinib
3
Procarbazine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Astrocytoma
×
selinexor
×
Clear all
NCT01986348
2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2
Terminated
76 enrolled
16 charts